Advertisement

A bubble in the biotech sector?

Growth-starved investors have piled into the Nasdaq in recent years, swelling the exchange's biotech index.

US biotechnology stocks have hit turbulence. The Nasdaq Biotechnology index has slid by 10% from its July peak. Since the March 2009 low, it has risen almost sevenfold, compared to a fourfold increase in the Nasdaq Composite index. In recent years, "growth-starved investors" have piled into the sector, happily paying top dollar for impressive sales growth, says Charley Grant in The Wall Street Journal.

Advertisement - Article continues below

In the second quarter, for instance, the top five biotechs by market value managed to grow combined sales by a total of 31% year-on-year. The overall stockmarket, as measured by the S&P 500, grew sales by just under 2%.

So as far as the bulls are concerned, high valuations are fully justified. But, as Ben Levisohn points out on barrons.com, "there comes a point when just rewards tip over into excess". Frothy flotations are one worry. "There has been an explosion of low-quality" initial public offerings, says Matarin Capital's Ralph Coutant. "It feels quite bubbly."

Furthermore, the Nasdaq Biotechnology index is on a price/earnings ratio of 85, compared to around 30 for the Nasdaq Composite (thisfigure peaked at almost 200 in 2000).The biotech sector is also on an eye-watering price-to-sales ratio of almost ten.

Not everyone is rattled. Star fund manger Neil Woodford has been "outspoken about his confidence in biotech stocks", say Julia Faurschou and Madison Marriage in the FT. But with signs of growth slowing at the bigger biotechs, making valuations harder to justify, fears of a correction seem likely to spread.

Advertisement
Advertisement

Recommended

The British equity market is shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Three biotech stocks on the cutting edge of medicine
Share tips

Three biotech stocks on the cutting edge of medicine

Investors are only now recognising the vast potential of biotech stocks. Here. Professional investor Dr Daniel Koller of BB Biotech AG picks three of …
31 Jul 2019
There are lots of reasons to be bearish – but you should stick with the bulls
Stockmarkets

There are lots of reasons to be bearish – but you should stick with the bulls

There are plenty of reasons to be gloomy about the stockmarkets. But the trend remains up, says Dominic Frisby. And you don’t want to bet against the …
17 Jul 2019
What gold, bonds and tech stocks have in common
Stockmarkets

What gold, bonds and tech stocks have in common

"Risk off" or "safe haven" assets such as gold and government bonds have been doing well lately. But so have riskier tech stocks. That seems to defy c…
10 Jul 2020

Most Popular

An economics lesson from my barber
Inflation

An economics lesson from my barber

On reopening his shop after lockdown, Dominic Frisby’s barber doubled his prices. It’s all part of the post-Covid inflation process – and we’re going …
8 Jul 2020
Can Rishi Sunak save the economy with stamp duty cuts and half-price meal deals?
UK Economy

Can Rishi Sunak save the economy with stamp duty cuts and half-price meal deals?

John Stepek runs his eye over the chancellor's £30bn stimulus package and asks if it's enough to get the economy back on its feet after months of lock…
9 Jul 2020
Have small companies lost their edge?
Sponsored

Have small companies lost their edge?

SPONSORED CONTENT – The tectonic plates beneath the modern investing landscape appear to have started moving in new directions
26 Jun 2020